Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting

Phase 2

Nab-SirolimusTrial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Sponsor:

Aadi Bioscience, Inc.

Code:

NCT05997056

Conditions

Neuroendocrine Tumors

NET

Pancreatic Neuroendocrine Tumor

Gastrointestinal Neuroendocrine Tumor

Pulmonary Neuroendocrine Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

nab-sirolimus

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by Aadi Bioscience, Inc. on 2024-07-16.